Method of treating cognitive impairments and schizophrenias

Abstract

The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT 1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

1 . A method of treating a patient suffering from a disorder of cognitive impairment, treatment-resistant schizophrenia, treatment-resistant schizophrenia with cognitive impairments, inveterate schizophrenia, inveterate schizophrenia with cognitive impairments, chronic schizophrenia, or chronic schizophrenia with cognitive impairments, which comprises administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof, wherein said patient is a mammal: 
       
         
           
           
               
               
           
         
         wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond. 
       
     
     
         2 . The method of  claim 1  wherein the disorder is cognitive impairment. 
     
     
         3 . The method of  claim 2  wherein the disorder is cognitive impairment caused by treatment-resistant schizophrenia, cognitive impairment caused by inveterate schizophrenia, or cognitive impairment caused by chronic schizophrenia. 
     
     
         4 . The method of  claim 1  wherein the disorder is treatment-resistant schizophrenia, inveterate schizophrenia or chronic schizophrenia, which fails to respond adequately to currently available antipsychotic drugs. 
     
     
         5 . The method of  claim 1  wherein the disorder is treatment-resistant schizophrenia with cognitive impairments, inveterate schizophrenia with cognitive impairments or chronic schizophrenia with cognitive impairments, which fails to respond adequately to currently available antipsychotic drugs. 
     
     
         6 . The method of  claim 4  wherein the currently available antipsychotic drugs are chlorpromazine, haloperidol, sulpiride, fluphenazine, perphenazine, thioridazine, pimozide, zotepine, risperidone, olanzapine, quetiapine, or amisulpride. 
     
     
         7 . The method of  claim 5  wherein the currently available antipsychotic drugs are chlorpromazine, haloperidol, sulpiride, fluphenazine, perphenazine, thioridazine, pimozide, zotepine, risperidone, olanzapine, quetiapine, or amisulpride. 
     
     
         8 . The method of  claim 4  wherein the currently available antipsychotic drugs are 1-3 typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride. 
     
     
         9 . The method of  claim 5  wherein the currently available antipsychotic drugs are 1-3 typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride. 
     
     
         10 . The method of  claim 4  wherein the currently available antipsychotic drugs are two typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride. 
     
     
         11 . The method of  claim 5  wherein the currently available antipsychotic drugs are two typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride. 
     
     
         12 . The method of  claim 4  wherein the currently available antipsychotic drugs are one to two typical antipsychotic drugs selected from chlorpromazine and haloperidol, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride. 
     
     
         13 . The method of  claim 5  wherein the currently available antipsychotic drugs are one to two typical antipsychotic drugs selected from chlorpromazine and haloperidol, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride. 
     
     
         14 . The method of  claim 4  wherein the currently available antipsychotic drugs are two typical antipsychotic drugs selected from chlorpromazine and haloperidol, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride. 
     
     
         15 . The method of  claim 5  wherein the currently available antipsychotic drugs are two typical antipsychotic drugs selected from chlorpromazine and haloperidol, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride. 
     
     
         16 . The method according to any one of  claims 1 - 15  wherein the carbostyril compound is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxyl}-3,4-dihydrocarbostyril.